Impact of Definitive Drug–Drug Interaction Testing on Medication Management and Patient Care View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-10-08

AUTHORS

Renée J. G. Arnold, Jun Tang, Joshua Schrecker, Cheryl Hild

ABSTRACT

BACKGROUND AND OBJECTIVE: Aegis Sciences Corporation developed a test (InterACT Rx) that objectively and definitively identifies substances known to interact with drug-drug interaction-prone medications commonly prescribed in the treatment of chronic pain and behavioral health disorders. The objective of this study was to assess the severity of identified drug-drug interactions, the reduction in the frequency and severity of identified drug-drug interactions, and the impact of the test on healthcare utilization. METHODS: Patients with chronic pain, behavioral health disorders, or both who had one or more drug-drug interaction tests and one or more drug-drug interactions identified in the study period were included. Drug-drug interaction test results described the number and severity of interactions and detected substances involved in drug-drug interactions. Patients' electronic medical records were obtained to analyze outpatient visits and prescription medications. The cost of outpatient visits was based on the Medicare Physician Fee Schedule. Outcomes were compared between the pre- and post-study index periods to determine the impact of the drug-drug interaction test on patient care. RESULTS: A total of 262 patients were included. The majority of drug-drug interactions detected (77.9%) at index were of moderate severity. The number of monthly all-cause and pain-related outpatient visits was reduced in the post-index period compared with the pre-index period (0.74-0.54 and 0.69-0.49, respectively). Associated costs were reduced from US$64.92 to US$51.20, and from US$62.42 to US$47.62, (p < 0.0001 for both) for all-cause and pain-related outpatient visits, respectively. Follow-up drug-drug interaction testing for 43 patients revealed that previously reported drug-drug interactions at the index test were no longer identified in the subsequent test for 39.5% of patients. CONCLUSIONS: Employing a definitive test to detect substances whose interactions may cause adverse drug events can enhance a provider's insights, drive clinical decision making, and improve patient outcomes. More... »

PAGES

217-224

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40801-018-0143-z

DOI

http://dx.doi.org/10.1007/s40801-018-0143-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1107480632

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30298445


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Icahn School of Medicine at Mount Sinai, New York, NY USA", 
          "id": "http://www.grid.ac/institutes/grid.59734.3c", 
          "name": [
            "Arnold Consultancy & Technology, LLC, 15 West 72nd Street, 23rd Floor, New York, NY 10023 USA", 
            "Icahn School of Medicine at Mount Sinai, New York, NY USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Arnold", 
        "givenName": "Ren\u00e9e J. G.", 
        "id": "sg:person.01352567371.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352567371.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Navigant Consulting, Inc., San Francisco, CA USA", 
          "id": "http://www.grid.ac/institutes/grid.502871.9", 
          "name": [
            "Navigant Consulting, Inc., San Francisco, CA USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tang", 
        "givenName": "Jun", 
        "id": "sg:person.014241622356.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014241622356.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Aegis Sciences Corporation, Nashville, TN USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Aegis Sciences Corporation, Nashville, TN USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schrecker", 
        "givenName": "Joshua", 
        "id": "sg:person.011253720356.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011253720356.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Aegis Sciences Corporation, Nashville, TN USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Aegis Sciences Corporation, Nashville, TN USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hild", 
        "givenName": "Cheryl", 
        "id": "sg:person.01331064414.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331064414.85"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11606-010-1256-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034148267", 
          "https://doi.org/10.1007/s11606-010-1256-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1472-6904-9-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018942190", 
          "https://doi.org/10.1186/1472-6904-9-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11594710-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038171128", 
          "https://doi.org/10.2165/11594710-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40263-013-0114-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024373126", 
          "https://doi.org/10.1007/s40263-013-0114-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40264-015-0281-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001160740", 
          "https://doi.org/10.1007/s40264-015-0281-0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-10-08", 
    "datePublishedReg": "2018-10-08", 
    "description": "BACKGROUND AND OBJECTIVE: Aegis Sciences Corporation developed a test (InterACT Rx\u2122) that objectively and definitively identifies substances known to interact with drug-drug interaction-prone medications commonly prescribed in the treatment of chronic pain and behavioral health disorders. The objective of this study was to assess the severity of identified drug-drug interactions, the reduction in the frequency and severity of identified drug-drug interactions, and the impact of the test on healthcare utilization.\nMETHODS: Patients with chronic pain, behavioral health disorders, or both who had one or more drug-drug interaction tests and one or more drug-drug interactions identified in the study period were included. Drug-drug interaction test results described the number and severity of interactions and detected substances involved in drug-drug interactions. Patients' electronic medical records were obtained to analyze outpatient visits and prescription medications. The cost of outpatient visits was based on the Medicare Physician Fee Schedule. Outcomes were compared between the pre- and post-study index periods to determine the impact of the drug-drug interaction test on patient care.\nRESULTS: A total of 262 patients were included. The majority of drug-drug interactions detected (77.9%) at index were of moderate severity. The number of monthly all-cause and pain-related outpatient visits was reduced in the post-index period compared with the pre-index period (0.74-0.54 and 0.69-0.49, respectively). Associated costs were reduced from US$64.92 to US$51.20, and from US$62.42 to US$47.62, (p\u00a0<\u00a00.0001 for both) for all-cause and pain-related outpatient visits, respectively. Follow-up drug-drug interaction testing for 43 patients revealed that previously reported drug-drug interactions at the index test were no longer identified in the subsequent test for 39.5% of patients.\nCONCLUSIONS: Employing a definitive test to detect substances whose interactions may cause adverse drug events can enhance a provider's insights, drive clinical decision making, and improve patient outcomes.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40801-018-0143-z", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1051855", 
        "issn": [
          "2199-1154", 
          "2198-9788"
        ], 
        "name": "Drugs - Real World Outcomes", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "5"
      }
    ], 
    "keywords": [
      "drug-drug interactions", 
      "outpatient visits", 
      "behavioral health disorders", 
      "electronic medical records", 
      "chronic pain", 
      "health disorders", 
      "patient care", 
      "more drug-drug interactions", 
      "post-index period", 
      "pre-index period", 
      "patients' electronic medical records", 
      "adverse drug events", 
      "interaction test", 
      "clinical decision making", 
      "healthcare utilization", 
      "prescription medications", 
      "drug events", 
      "medical records", 
      "patient outcomes", 
      "medication management", 
      "Medicare Physician Fee Schedule", 
      "moderate severity", 
      "patients", 
      "index period", 
      "study period", 
      "providers insights", 
      "visits", 
      "severity", 
      "physician fee schedule", 
      "medications", 
      "pain", 
      "severity of interactions", 
      "associated costs", 
      "care", 
      "disorders", 
      "outcomes", 
      "fee schedule", 
      "definitive test", 
      "cause", 
      "index test", 
      "period", 
      "subsequent tests", 
      "interaction test results", 
      "test", 
      "substances", 
      "treatment", 
      "total", 
      "pre", 
      "interaction testing", 
      "majority", 
      "objective", 
      "index", 
      "management", 
      "impact", 
      "schedule", 
      "records", 
      "testing", 
      "study", 
      "number", 
      "background", 
      "test results", 
      "decision making", 
      "reduction", 
      "events", 
      "frequency", 
      "interaction", 
      "insights", 
      "utilization", 
      "results", 
      "cost", 
      "making", 
      "corporations", 
      "Aegis Sciences Corporation", 
      "Sciences Corporation", 
      "drug-drug interaction-prone medications", 
      "interaction-prone medications", 
      "more drug-drug interaction tests", 
      "drug-drug interaction tests", 
      "Drug-drug interaction test results", 
      "post-study index periods", 
      "pain-related outpatient visits", 
      "Definitive Drug\u2013Drug Interaction Testing", 
      "Drug\u2013Drug Interaction Testing"
    ], 
    "name": "Impact of Definitive Drug\u2013Drug Interaction Testing on Medication Management and Patient Care", 
    "pagination": "217-224", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1107480632"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40801-018-0143-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30298445"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40801-018-0143-z", 
      "https://app.dimensions.ai/details/publication/pub.1107480632"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:41", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_770.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40801-018-0143-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0143-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0143-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0143-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0143-z'


 

This table displays all metadata directly associated to this object as RDF triples.

193 TRIPLES      22 PREDICATES      114 URIs      101 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40801-018-0143-z schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Naaca8013314d4d02b12dde94d9c0cdaa
4 schema:citation sg:pub.10.1007/s11606-010-1256-6
5 sg:pub.10.1007/s40263-013-0114-6
6 sg:pub.10.1007/s40264-015-0281-0
7 sg:pub.10.1186/1472-6904-9-8
8 sg:pub.10.2165/11594710-000000000-00000
9 schema:datePublished 2018-10-08
10 schema:datePublishedReg 2018-10-08
11 schema:description BACKGROUND AND OBJECTIVE: Aegis Sciences Corporation developed a test (InterACT Rx<sup>™</sup>) that objectively and definitively identifies substances known to interact with drug-drug interaction-prone medications commonly prescribed in the treatment of chronic pain and behavioral health disorders. The objective of this study was to assess the severity of identified drug-drug interactions, the reduction in the frequency and severity of identified drug-drug interactions, and the impact of the test on healthcare utilization. METHODS: Patients with chronic pain, behavioral health disorders, or both who had one or more drug-drug interaction tests and one or more drug-drug interactions identified in the study period were included. Drug-drug interaction test results described the number and severity of interactions and detected substances involved in drug-drug interactions. Patients' electronic medical records were obtained to analyze outpatient visits and prescription medications. The cost of outpatient visits was based on the Medicare Physician Fee Schedule. Outcomes were compared between the pre- and post-study index periods to determine the impact of the drug-drug interaction test on patient care. RESULTS: A total of 262 patients were included. The majority of drug-drug interactions detected (77.9%) at index were of moderate severity. The number of monthly all-cause and pain-related outpatient visits was reduced in the post-index period compared with the pre-index period (0.74-0.54 and 0.69-0.49, respectively). Associated costs were reduced from US$64.92 to US$51.20, and from US$62.42 to US$47.62, (p &lt; 0.0001 for both) for all-cause and pain-related outpatient visits, respectively. Follow-up drug-drug interaction testing for 43 patients revealed that previously reported drug-drug interactions at the index test were no longer identified in the subsequent test for 39.5% of patients. CONCLUSIONS: Employing a definitive test to detect substances whose interactions may cause adverse drug events can enhance a provider's insights, drive clinical decision making, and improve patient outcomes.
12 schema:genre article
13 schema:inLanguage en
14 schema:isAccessibleForFree true
15 schema:isPartOf N5f163740b0994241add4b0749900a258
16 Ncb35b58e8e064c61be3bd8fdad2f4be2
17 sg:journal.1051855
18 schema:keywords Aegis Sciences Corporation
19 Definitive Drug–Drug Interaction Testing
20 Drug-drug interaction test results
21 Drug–Drug Interaction Testing
22 Medicare Physician Fee Schedule
23 Sciences Corporation
24 adverse drug events
25 associated costs
26 background
27 behavioral health disorders
28 care
29 cause
30 chronic pain
31 clinical decision making
32 corporations
33 cost
34 decision making
35 definitive test
36 disorders
37 drug events
38 drug-drug interaction tests
39 drug-drug interaction-prone medications
40 drug-drug interactions
41 electronic medical records
42 events
43 fee schedule
44 frequency
45 health disorders
46 healthcare utilization
47 impact
48 index
49 index period
50 index test
51 insights
52 interaction
53 interaction test
54 interaction test results
55 interaction testing
56 interaction-prone medications
57 majority
58 making
59 management
60 medical records
61 medication management
62 medications
63 moderate severity
64 more drug-drug interaction tests
65 more drug-drug interactions
66 number
67 objective
68 outcomes
69 outpatient visits
70 pain
71 pain-related outpatient visits
72 patient care
73 patient outcomes
74 patients
75 patients' electronic medical records
76 period
77 physician fee schedule
78 post-index period
79 post-study index periods
80 pre
81 pre-index period
82 prescription medications
83 providers insights
84 records
85 reduction
86 results
87 schedule
88 severity
89 severity of interactions
90 study
91 study period
92 subsequent tests
93 substances
94 test
95 test results
96 testing
97 total
98 treatment
99 utilization
100 visits
101 schema:name Impact of Definitive Drug–Drug Interaction Testing on Medication Management and Patient Care
102 schema:pagination 217-224
103 schema:productId N1df5ca0b58d04441b1ff321f0de91271
104 N24ff2fc96a314304ad45a7fd50063b41
105 Nc60ce7f30275407a88e52c94b58a98c8
106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107480632
107 https://doi.org/10.1007/s40801-018-0143-z
108 schema:sdDatePublished 2021-12-01T19:41
109 schema:sdLicense https://scigraph.springernature.com/explorer/license/
110 schema:sdPublisher N8ab8ac138b1d4c1d9d6c814c5fcf4cb9
111 schema:url https://doi.org/10.1007/s40801-018-0143-z
112 sgo:license sg:explorer/license/
113 sgo:sdDataset articles
114 rdf:type schema:ScholarlyArticle
115 N01c5eabb0e4a4d0bb414b9a39724e29a rdf:first sg:person.011253720356.21
116 rdf:rest Nb2325bc5332a4175b084bd09554af29e
117 N1df5ca0b58d04441b1ff321f0de91271 schema:name pubmed_id
118 schema:value 30298445
119 rdf:type schema:PropertyValue
120 N24ff2fc96a314304ad45a7fd50063b41 schema:name dimensions_id
121 schema:value pub.1107480632
122 rdf:type schema:PropertyValue
123 N5f163740b0994241add4b0749900a258 schema:issueNumber 4
124 rdf:type schema:PublicationIssue
125 N8ab8ac138b1d4c1d9d6c814c5fcf4cb9 schema:name Springer Nature - SN SciGraph project
126 rdf:type schema:Organization
127 N94c3655571d14016bcdc1887817e0757 rdf:first sg:person.014241622356.12
128 rdf:rest N01c5eabb0e4a4d0bb414b9a39724e29a
129 Naaca8013314d4d02b12dde94d9c0cdaa rdf:first sg:person.01352567371.26
130 rdf:rest N94c3655571d14016bcdc1887817e0757
131 Nb2325bc5332a4175b084bd09554af29e rdf:first sg:person.01331064414.85
132 rdf:rest rdf:nil
133 Nc60ce7f30275407a88e52c94b58a98c8 schema:name doi
134 schema:value 10.1007/s40801-018-0143-z
135 rdf:type schema:PropertyValue
136 Ncb35b58e8e064c61be3bd8fdad2f4be2 schema:volumeNumber 5
137 rdf:type schema:PublicationVolume
138 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
139 schema:name Medical and Health Sciences
140 rdf:type schema:DefinedTerm
141 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
142 schema:name Clinical Sciences
143 rdf:type schema:DefinedTerm
144 sg:journal.1051855 schema:issn 2198-9788
145 2199-1154
146 schema:name Drugs - Real World Outcomes
147 schema:publisher Springer Nature
148 rdf:type schema:Periodical
149 sg:person.011253720356.21 schema:affiliation grid-institutes:None
150 schema:familyName Schrecker
151 schema:givenName Joshua
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011253720356.21
153 rdf:type schema:Person
154 sg:person.01331064414.85 schema:affiliation grid-institutes:None
155 schema:familyName Hild
156 schema:givenName Cheryl
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01331064414.85
158 rdf:type schema:Person
159 sg:person.01352567371.26 schema:affiliation grid-institutes:grid.59734.3c
160 schema:familyName Arnold
161 schema:givenName Renée J. G.
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352567371.26
163 rdf:type schema:Person
164 sg:person.014241622356.12 schema:affiliation grid-institutes:grid.502871.9
165 schema:familyName Tang
166 schema:givenName Jun
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014241622356.12
168 rdf:type schema:Person
169 sg:pub.10.1007/s11606-010-1256-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034148267
170 https://doi.org/10.1007/s11606-010-1256-6
171 rdf:type schema:CreativeWork
172 sg:pub.10.1007/s40263-013-0114-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024373126
173 https://doi.org/10.1007/s40263-013-0114-6
174 rdf:type schema:CreativeWork
175 sg:pub.10.1007/s40264-015-0281-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001160740
176 https://doi.org/10.1007/s40264-015-0281-0
177 rdf:type schema:CreativeWork
178 sg:pub.10.1186/1472-6904-9-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018942190
179 https://doi.org/10.1186/1472-6904-9-8
180 rdf:type schema:CreativeWork
181 sg:pub.10.2165/11594710-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038171128
182 https://doi.org/10.2165/11594710-000000000-00000
183 rdf:type schema:CreativeWork
184 grid-institutes:None schema:alternateName Aegis Sciences Corporation, Nashville, TN USA
185 schema:name Aegis Sciences Corporation, Nashville, TN USA
186 rdf:type schema:Organization
187 grid-institutes:grid.502871.9 schema:alternateName Navigant Consulting, Inc., San Francisco, CA USA
188 schema:name Navigant Consulting, Inc., San Francisco, CA USA
189 rdf:type schema:Organization
190 grid-institutes:grid.59734.3c schema:alternateName Icahn School of Medicine at Mount Sinai, New York, NY USA
191 schema:name Arnold Consultancy & Technology, LLC, 15 West 72nd Street, 23rd Floor, New York, NY 10023 USA
192 Icahn School of Medicine at Mount Sinai, New York, NY USA
193 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...